• Schrödinger signed a strategic collaboration and software agreement with Bristol Myers Squibb to deploy its AI co-scientist Bunsen in BMS research.
• Deal expands BMS use of Schrödinger’s computational platform, aiming to speed molecule prioritization and drug discovery decisions.
• Collaboration includes development of new Bunsen functionality, integrating Schrödinger workflows with RetroSynth for AI-driven synthesis planning.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.